Bayer and Onyx have multiple clinical trials underway for individuals with lung cancer.  A few of these trials are highlighted below.  For a more comprehensive list of Nexavar® (sorafenib) tablets clinical trials, please visit clinicaltrials.gov or call 1-866-639-2827.

For more information on each trial, click on the green study title to view the listing on clinicaltrials.gov.

Phase 3 Study of Nexavar in Combination with the Agents Gemcitabine and Cisplatin
Study Design: Randomized, double-blind placebo-controlled trial
Patients: Stage IIIb-IV non-small cell lung cancer (NSCLC) patients of all histologies who have not received prior systemic anticancer treatment
Purpose: To determine the effectiveness of Nexavar plus the chemotherapeutic agents gemcitabine and cisplatin when compared to the chemotherapeutic agents alone by assessing the difference in overall survival and disease progression, as well as to evaluate other measures of efficacy and safety
Location: Ex-U.S.

Phase 2 Single-Agent Trial*
Enrollment completed
Study Design:  Randomized, placebo-controlled study
Patients:  Patients with refractory non-small cell lung cancer who have progressed after at least two prior chemotherapy regimens
Purpose:   To determine the effectiveness of Nexavar by assessing the difference in disease progression, as well as evaluate other measures of efficacy such as median progression-free survival and overall survival
Location: U.S.

Phase 2 Study of Nexavar in Combination with the Agent Pemetrexed Disodium (Alimta)*
Study Design: Randomized, placebo-controlled study
Patients: Stage IIIb-IV non-small cell lung cancer (NSCLC) patients, who have progressed after one prior chemotherapy regimen
Purpose: To determine the effectiveness of Nexavar plus Alimta when compared to Alimta alone by assessing the difference in overall survival and disease progression, as well as to evaluate other measures of efficacy and safety
Location: U.S.

Phase 2 Study of Nexavar in Combination with the Agents Pemetrexed and Carboplatin*
Study Design: Randomized, double-blind, placebo-controlled trial
Patients: Stage IIIb-IV non-small cell lung cancer (NSCLC) patients of all histologies who have had no prior systemic chemotherapy
Purpose: To determine the effectiveness of Nexavar plus pemetrexed and carboplatin when compared to pemetrexed and carboplatin alone by assessing the difference in disease progression and overall survival, as well as to evaluate other measures of efficacy and safety
Location: Germany

* Not a company-sponsored trial.